167 related articles for article (PubMed ID: 22747425)
1. PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update.
Gur S; Kadowitz PJ; Serefoglu EC; Hellstrom WJ
Curr Pharm Des; 2012; 18(34):5590-606. PubMed ID: 22747425
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
Ioakeimidis N; Kostis JB
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):53-64. PubMed ID: 24281316
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C
Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
[TBL] [Abstract][Full Text] [Related]
4. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
[TBL] [Abstract][Full Text] [Related]
7. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
8. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
9. [Optimization of the use of phosphodiesterase-5 inhibitors].
Pushkar' DIu; Segal AS
Urologiia; 2012; (4):79-80, 82. PubMed ID: 23116030
[No Abstract] [Full Text] [Related]
10. The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis.
Eryildirim B; Aktas A; Kuyumcuoglu U; Faydaci G; Tarhan F; Ozgül A
Int J Impot Res; 2010; 22(6):349-54. PubMed ID: 20981108
[TBL] [Abstract][Full Text] [Related]
11. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME).
Shindel AW
J Sex Med; 2009 Jul; 6(7):1794-808; quiz 1793, 1809-10. PubMed ID: 19575771
[TBL] [Abstract][Full Text] [Related]
12. Exploring the association between erectile rigidity and treatment adherence with sildenafil.
Mazzola CR; Deveci S; Teloken P; Mulhall JP
J Sex Med; 2013 Jul; 10(7):1861-6. PubMed ID: 23253943
[TBL] [Abstract][Full Text] [Related]
13. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
[TBL] [Abstract][Full Text] [Related]
14. Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue.
Oger S; Behr-Roussel D; Gorny D; Lecoz O; Lebret T; Denoux Y; Faix A; Leriche A; Wayman C; Alexandre L; Giuliano F
J Sex Med; 2009 Mar; 6(3):836-47. PubMed ID: 19143907
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
[TBL] [Abstract][Full Text] [Related]
16. A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of erectile dysfunction.
Martin AL; Huelin R; Wilson D; Foster TS; Mould JF
J Sex Med; 2013 May; 10(5):1389-400. PubMed ID: 23347555
[TBL] [Abstract][Full Text] [Related]
17. [Sildenafil assumption and acute effects on the uroflowmetric parameters].
Masciovecchio S; Del Rosso A; Di Pierro ED; Saldutto P; Paradiso Galatioto G; Vicentini C
Minerva Urol Nefrol; 2013 Sep; 65(3):205-9. PubMed ID: 23872631
[TBL] [Abstract][Full Text] [Related]
18. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
Scranton RE; Goldstein I; Stecher VJ
J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity.
McVary KT; Siegel RL; Carlsson M
Urology; 2008 Sep; 72(3):575-9. PubMed ID: 18597830
[TBL] [Abstract][Full Text] [Related]
20. Versatile effects of sildenafil: recent pharmacological applications.
Uthayathas S; Karuppagounder SS; Thrash BM; Parameshwaran K; Suppiramaniam V; Dhanasekaran M
Pharmacol Rep; 2007; 59(2):150-63. PubMed ID: 17556793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
